![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Materials]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Materials)
1MB |
| Item Type: | Article |
|---|---|
| Title: | Occurrence and risk factors of relapse activity after vaccination against COVID-19 in people with multiple sclerosis: 1-year follow-up results from a nationwide longitudinal observational study |
| Creators Name: | Fneish, F., Frahm, N., Peters, M., Ellenberger, D., Haas, J., Löbermann, M., Pöhlau, D., Röper, A.L., Schilling, S., Stahmann, A., Temmes, H., Paul, F. and Zettl, U.K. |
| Abstract: | Several studies reported post-SARS-CoV-2-vaccination (PV) symptoms. Even people with multiple sclerosis (PwMS) have concerns about disease activity following the SARS-CoV-2 vaccination. We aimed to determine the proportion of PwMS with PV relapses, the PV annualized relapse rate (ARR), the time from vaccination to subsequent relapses, and identify sociodemographic/clinical risk factors for PV relapses. PwMS were surveyed several times at baseline and four follow-ups as part of a longitudinal observational study regarding the safety and tolerability of the SARS-CoV-2 vaccination. The inclusion criteria for this analysis were age ≥18 years, ≥1 SARS-CoV-2 vaccination, and ≥1-year observation period since initial vaccination. Of 2466 PwMS, 13.8% reported PV relapses (mostly after second [N = 147] or booster vaccination [N = 145]) at a median of 8.0 (first/third quantile: 3.55/18.1) weeks PV, with the shortest period following initial vaccination (3.95 weeks). The ARR was 0.153 (95% confidence interval: 0.138-0.168), with a median observation period since initial vaccination of 1.2 years. Risk factors for PV relapses were younger age, female gender, moderate-severe disability levels, concurrent autoimmune diseases, relapsing-remitting MS courses, no DMT, and relapses within the year prior to the first vaccination. Patients' health conditions before/during initial vaccination may play a more important role in PV relapse occurrence than vaccination per se. |
| Keywords: | SARS-CoV-2, Vaccination, Multiple Sclerosis, Relapse, Side Effects |
| Source: | Vaccines |
| ISSN: | 2076-393X |
| Publisher: | MDPI |
| Volume: | 11 |
| Number: | 12 |
| Page Range: | 1859 |
| Date: | 16 December 2023 |
| Official Publication: | https://doi.org/10.3390/vaccines11121859 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
